Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
UltraDx Bio
UltraDx Bio specializes in high-sensitivity protein detection technology.
Sector
Subsector
total rounds
total raised
Maven Biotechnologies
Maven Biotechnology develops real-time and label-free imaging technology for protein microarrays, cell-based assays and biomarker detection.
Sector
Subsector
Keywords
Location
total rounds
total raised
Biospin
Biospin provides a revolutionary microbial detection system for F&B, water, and pharmaceutical products.
Sector
Subsector
Keywords
Location
total rounds
TargetDx Laboratory
TargetDx Laboratory specializes in early-stage non-small cell lung cancer detection using protein biomarkers and proprietary algorithms.
Sector
Subsector
Keywords
Location
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 29.07.2024. Their latest investor Bio-Techne. Their latest round Series A
Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bio-Techne
Bio-Techne empowers researchers with reagents, instruments, manufacturing, and testing services in Life Science and Clinical Diagnostics.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
CDH Investments
CDH Investments is an international alternative asset fund manager with over $2.0 billion of committed capital under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Sequoia Capital China
Sequoia Capital China is a venture capital firm that invests in fintech companies at various stages of growth.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors6
Number of lead investors
Number of investors
Bio-Techne
Bio-Techne empowers researchers with reagents, instruments, manufacturing, and testing services in Life Science and Clinical Diagnostics.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Kim Kelderman
Kim Kelderman is the President of Diagnostics and Genomics of Bio-Techne. He previously worked at Guangzhou Life Technologies DaAn Diagnostics Co., Ltd. China as a Member Board Of Directors. Kim Kelderman attended Columbia Business School.
Yonghua Capital
Yongyong Investment specializes in equity investment management through its subsidiary Shanghai Chung Hua Investment Management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Vikram Bajaj
Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Vik's research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development. He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy's LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.
current job
People
Employee Profiles3
Activity
Recent News2
The graph reveals the ratio (%) of positive news articles in a chosen time range